Accession Number : AD1047191


Title :   Developing Novel Therapeutics Targeting Undifferentiated and Castration-Resistant Prostate Cancer Stem Cells


Descriptive Note : Technical Report,29 Sep 2015,28 Sep 2016


Corporate Author : University of Texas MD Anderson Cancer Center Houston United States


Personal Author(s) : Tang,Dean G


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1047191.pdf


Report Date : 01 Oct 2016


Pagination or Media Count : 38


Abstract : The main objective of this DOD-supported project is to identify and develop novel therapeutics to target the undifferentiated (PSA-/lo), castration-resistant PCSCs. We proposed to achieve this objective with two Specific Aims: 1) To perform phage display library (PDL) screening in PSA-/lo PCa cells to identify PCSC-specific homing peptides; and 2) To perform unbiased drug library screening to identify novel PCSC-targeting chemicals. In the past year, we have accomplished all goals in Aim 2 with a comprehensive publication in Oncotarget. We have also made some progress for Specific Aim 1. Dr. Tang, the PI of this grant, together with most lab members, moved from the M.D Anderson Cancer Center (MDACC) to Roswell Park Cancer Institute (RPCI) on June 1 of 2016. During the period of May 1 early July of 2016, the lab had been mostly focused on moving related matters and therefore there was a gap in executing experiments related to this project. In the last year of the grant period, we request the transfer of the remaining balance for this grant to the RPCI in order to complete all goals proposed in Aim 1.


Descriptors :   prostate cancer , stem cells , peptides , drugs


Subject Categories : Medicine and Medical Research
      Pharmacology
      Biochemistry


Distribution Statement : APPROVED FOR PUBLIC RELEASE